2016
DOI: 10.1016/j.bmcl.2016.06.070
|View full text |Cite
|
Sign up to set email alerts
|

Novel potent pyridoxine-based inhibitors of AChE and BChE, structural analogs of pyridostigmine, with improved in vivo safety profile

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 21 publications
(4 citation statements)
references
References 18 publications
0
4
0
Order By: Relevance
“…This disease is associated with loss of cholinergic neurons in the brain and a decreased level of ACh. The major therapeutic target in Alzheimer's treatment approaches is the inhibition of brain AChE [26][27][28]. Additionally, in Alzheimer's and other neurologic diseases, the high level of dyshomeostatis of metal ions, especially iron ions, seriously affects brain function.…”
Section: Introductionmentioning
confidence: 99%
“…This disease is associated with loss of cholinergic neurons in the brain and a decreased level of ACh. The major therapeutic target in Alzheimer's treatment approaches is the inhibition of brain AChE [26][27][28]. Additionally, in Alzheimer's and other neurologic diseases, the high level of dyshomeostatis of metal ions, especially iron ions, seriously affects brain function.…”
Section: Introductionmentioning
confidence: 99%
“…The effect of the drug starts in 15-30 min, reaches maximum in 1-2 hours, and lasts 3-4 hours or longer. Pyridostigmine bromide, used for the treatment of MG and for protection against exposure to nerve agents, is a carbamate-derived reversible AChE inhibitor [23][24][25]. Due to the quaternary amine structure, it is relatively weakly absorbed from the gastrointestinal system.…”
Section: Pyridostigminementioning
confidence: 99%
“…In particular, pyridoxine molecules carrying a 5-ethenyl substituent possess anti-inflammatory properties [1], 6-phenylethenyl substituted pyridoxines have been described as purine receptor antagonists [2], and 2-ethenyl derivatives possess antitumor activity [3]. In our group, we have systematically studied the chemistry and biological activity of pyridoxine derivatives (e.g., [4][5][6][7][8]). Recently, we described a number of cis-and trans-5-alkenyl substituted pyridoxines which demonstrated promising antitumor activity [7].…”
Section: Introductionmentioning
confidence: 99%